Ado-trastuzumab emtansine Intravenous and Octreotide Acetate

• Generic Name: ado-trastuzumab emtansine
• Dosage Forms: n.a.
• Other Brand Names: Kadcyla

Ado-trastuzumab emtansine injection is used to treat HER2-positive metastatic breast cancer (cancer that has spread to other parts of the body) in patients who have already received other medicines that did not work well. HER2 protein is produced by some breast tumors. Ado-trastuzumab emtansine interferes with the growth of this protein which also prevents tumor growth. The tumor cells will then be destroyed by the body.

Ado-trastuzumab emtansine is to be given only by or under the immediate supervision of your doctor.

• Generic Name: octreotide
• Dosage Forms: n.a.
• Other Brand Names: Sandostatin, Sandostatin LAR Depot

Symptomatic treatment to suppress or inhibit severe diarrhea and flushing associated with carcinoid tumors.

Long-acting suspension is used for long-term management of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors in patients in whom initial treatment with octreotide immediate-release injection has been shown to be effective and tolerated (designated an orphan drug by FDA for this use).

Acute management of potentially life-threatening hypotension associated with carcinoid crisis.

Prophylaxis of carcinoid crisis that might be precipitated by anesthesia, surgery, initiation of chemotherapy, or infection.

Management of profuse watery diarrhea associated with vasoactive intestinal polypeptide (VIP)-secreting tumors.

Long-acting suspension is used for long-term management of profuse watery diarrhea associated with VIP-secreting tumors in patients who have been treated successfully with octreotide immediate-release injection (designated an orphan drug by FDA for this use).

Treatment to reduce growth hormone (GH) and insulin-like growth factor I (IGF-I) blood concentrations in patients with acromegaly who have had inadequate responses to or are not candidates for surgical resection, pituitary irradiation, and bromocriptine mesylate (at maximally tolerated doses).

Long-acting suspension is used for long-term therapy in patients who are candidates for medical therapy and who have been treated successfully with immediate-release injection (designated an orphan drug by FDA for this use). Long-acting suspension may be used in patients who are not candidates for surgery or who have had an inadequate response to surgery or patients who have had a suboptimal response to radiation therapy.

Has been used in a limited number of neonates and infants to stabilize plasma glucose levels prior to pancreatectomy, to treat recurrent post-operative hypoglycemia, and as an alternative medical treatment to diazoxide for control of hypoglycemia.